Xoc Pharmaceuticals Inc., a CNS-focused startup developing drugs for migraine prevention and Parkinson's disease (PD) maintenance, has closed a tranched $30 million series A financing led by New Enterprise Associates. The Los Gatos, Calif.-based company, founded by a team of Map Pharmaceuticals Inc. alumni, said the funds will enable it to complete preclinical testing and take its two lead compounds, XC-101 and XC-130, into the clinic.